Main Body
The response discusses long-term measures including:
1Role of stakeholders: pharmaceutical firms, patent/rare disease specialists, society at large, government
2Price cap solving one problem by creating another
3Disincentivizing research and development due to price caps
4Scientific development vs public upliftment
5Issue of regulatory frameworks (CESD)
6Price cap creating one problem by creating another one
7Disincentivizing research and development
8Distinction between research on high-cost drugs and medicines
9Social integration based on limited access to poor quality drug quality
10Hampering foreign investment due to unrealistic profit targets
The response continues with long-term measures:
1Government funding for rare disease drug development to remove profit incentive issue
2Engaging NGOs and civil society for taking up the issue of high-cost drugs
3Promote sustainable corporate governance
4Profit motive should be based on social upliftment and realize corporate social responsibility
5Providing with government research and development initiatives for high-cost sectors
6Promoting ease of doing business and business management should inculcate kushta kamina trust beneficial to all and not only for garnering wealth
180 words1 paragraphs
This is a continuation from previous page
- Comprehensive discussion of multiple stakeholder perspectives
- Addresses unintended consequences of price caps
- Links profit motive to research incentives
- Proposes multiple mechanisms for resolution
- Combines government, market, and civil society approaches
- Addresses both immediate and systemic issues
Topper
Sudipa Dutta
AIR 412092
Subject & Paper
GS4GS1
Topic
Long-term measures for pharmaceutical pricing issues
Policy solutions for access to medicines
Balancing profit motive with public health
Writing Stats
180
Total words
1
Paragraphs
policy-oriented and prescriptive
Tone